Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase patient had a partial hematologi… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Of 14 patients who started the study in late chr… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Among 64 patients initially in late-chronic phas… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had a complete hema… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic respons… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A CP patient had complete cytogenetic response u… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An acute-phase patient achieved complete hematol… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic phase (CP) patient had complete hemato… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had a complete cyto… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase (AP) patient improved to ch… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerate-phase patient had a complete cytog… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase patient had a return to chr… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had only a partial … (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Three CP patients, with the M351T variants detec… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase (CP) patient achieved a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had major cyto… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic respons… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC